Tag: oncolytic adenovirus market trends

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Oncolytic Adenovirus Market Over The Five-Year Period 2025–2029?

The oncolytic adenovirus market size has seen substantial growth recently. It is projected to increase from $122.31 billion in 2024 to $132.49 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.3%. The expansion observed in the past can be ascribed to a higher incidence of cancer, the escalating need for precise cancer treatments, increased investment in research and development, advancements in delivery techniques, and successful regulatory clearances.

The oncolytic adenovirus market size is projected to experience strong growth over the next few years. It is expected to expand to $181.71 billion by 2029, achieving a compound annual growth rate (CAGR) of 8.2%. The anticipated growth during this period can be attributed to the increasing prevalence and incidence of cancer, the expansion of combination therapies, advancements and approvals in regulations, technological improvements in virus engineering, and greater investment in oncology research. Significant trends identified for the forecast period include innovations in viral engineering techniques, sophisticated drug delivery systems, enhanced precision in tumor targeting, advanced immunotherapy combinations, and progress in patient monitoring and diagnostics.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

Which Drivers Are Supporting Growth Of The Oncolytic Adenovirus Market?

The future expansion of the oncolytic adenovirus market is anticipated to be significantly driven by the rising occurrence of cancer. Cancer, a condition where cells grow uncontrollably and spread throughout the body, is becoming more prevalent due to factors such as an aging global population, various lifestyle choices, environmental exposures, inherited genetic tendencies, and enhanced diagnostic methods. Oncolytic adenovirus presents a hopeful strategy for addressing this growing cancer incidence by specifically targeting and eliminating cancer cells. For example, in May 2024, data from the National Cancer Institute (NCI), a U.S. government body, indicated approximately 20 million new cancer cases and 9.7 million deaths globally, with forecasts suggesting an increase to 29.9 million cases and 15.3 million deaths by 2040. Additionally, in 2023, the Australian Bureau of Statistics, an Australian government entity, reported that 1.8% of Australians were living with cancer, with males (2.1%) being marginally more affected than females (1.6%), particularly individuals aged 75 and over. Consequently, the increasing frequency of cancer diagnoses is a key driver for the growth within the oncolytic adenovirus market.

What Are The Segment Types Shaping The Oncolytic Adenovirus Market?

The oncolytic adenovirusmarket covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses; Adenovirus Type 2-Based Oncolytic Viruses; Other Virus Types

2) By Application: Melanoma; Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Other Applications

3) By End-User: Hospitals; Cancer Research Institutes; Biotechnology Companies; Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based; Second-generation Adenovirus Type 5-based; Engineered Adenovirus Type 5-based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based; Second-generation Adenovirus Type 2-based; Engineered Adenovirus Type 2-based

3) By Other Virus Types: Modified Adenovirus Strains; Hybrid Adenovirus Types; Chimeric Adenoviruses

Which Ongoing Trends Are Expected To Shape The Oncolytic Adenovirus Market Outlook?

Leading companies within the oncolytic adenovirus market are increasingly concentrating on combination therapies, exemplified by VCN-01. This approach integrates oncolytic virotherapy with chemotherapy to enhance tumor targeting and improve therapeutic results. VCN-01 itself is an oncolytic adenovirus specifically engineered to selectively infect and destroy cancer cells, concurrently boosting the efficacy of chemotherapy. Illustratively, Theriva Biologics, a US-based clinical-stage immuno-oncology firm, announced in May 2024 that the U.S. Food and Drug Administration (FDA) had bestowed Fast Track Designation (FTD) upon its primary candidate, VCN-01. This FTD applies to VCN-01’s use alongside gemcitabine and nab-paclitaxel for treating metastatic pancreatic adenocarcinoma. Furthermore, VCN-01 functions as an oncolytic adenovirus by targeting and replicating within tumor cells, thereby aiding in the degradation of the tumor stroma, which is a significant impediment to effective cancer therapy.

Who Are The Core Companies Influencing The Oncolytic Adenovirus Market Landscape?

Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

What Are The Key Regional Factors Influencing The Oncolytic Adenovirus Market Growth?

North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Oncolytic Adenovirus Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp

Browse Through More Reports Similar to the Global Oncolytic Adenovirus Market 2025, By The Business Research Company

Virus Filtration Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/virus-filtration-global-market-report

Herpes Simplex Virus Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/herpes-simplex-virus-treatment-global-market-report

Human Papillomavirus Hpv Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/human-papillomavirus-hpv-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Oncolytic Adenovirus Market Growth Performance Trended Historically, And What Lies Ahead?

The market size for oncolytic adenovirus has witnessed considerable growth lately. It’s projected to rise from $122.31 billion in 2024 to $132.49 billion in 2025, registering a compound annual growth rate (CAGR) of 8.3%. The growth witnessed in the historical period is due to a surge in cancer cases, augmented demand for tailored cancer treatments, an increase in R&D funds, enhancement in delivery procedures, and regulatory approvals.

With a robust increase projected over the coming years, the oncolytic adenovirus market is anticipated to surge to$181.71 billion by 2029 at an 8.2% compound annual growth rate (CAGR). The substantial growth anticipated during this period is attributed to factors such as rising instances and prevalence of cancer, the extension of combination therapies, advancements and approvals in regulations, breakthroughs in virus engineering technology, as well as heightened investment in oncology research. The main trends forecasted during this period involve progresses in viral engineering methodologies, enhanced drug delivery systems, precision improvements in tumor targeting, superior combinations of immunotherapy, and advancements in patient monitoring and diagnostic procedures.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Oncolytic Adenovirus Market?

The relentless rise in cancer cases is set to further stimulate expansion in the oncolytic adenovirus market. This illness, defined by unregulated cell proliferation and dissemination to other body sites, has seen its prevalence escalate due to aging populations, lifestyle choices, environmental exposure, genetic predispositions, and superior detection techniques. Oncolytic adenoviruses specifically target and annihilate cancer cells, presenting a hopeful strategy to counter the mounting number of cancer incidents. For instance, reports released by the National Cancer Institute (NCI), a US governmental body, in May 2024 stated that the world witnessed nearly 20 million fresh cancer cases and 9.7 million fatalities, with a forecast for 2040 to burgeon to approximately 29.9 million cases and 15.3 million deaths. Moreover, statistics from the Australian Bureau of Statistics, a government agency in Australia, showed in 2023 that 1.8% of Australians were diagnosed with cancer, with a slightly higher proportion of men (2.1%) than women (1.6%) being afflicted, particularly those aged 75 and over. Consequently, the escalating occurrence of cancer is propelling the growth trajectory of the oncolytic adenovirus market.

Which Key Market Segments Comprise the Oncolytic Adenovirus Market and Drive Its Revenue Growth?

The oncolytic adenovirusmarket covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses; Adenovirus Type 2-Based Oncolytic Viruses; Other Virus Types

2) By Application: Melanoma; Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Other Applications

3) By End-User: Hospitals; Cancer Research Institutes; Biotechnology Companies; Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based; Second-generation Adenovirus Type 5-based; Engineered Adenovirus Type 5-based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based; Second-generation Adenovirus Type 2-based; Engineered Adenovirus Type 2-based

3) By Other Virus Types: Modified Adenovirus Strains; Hybrid Adenovirus Types; Chimeric Adenoviruses

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp

Which Areas Are Leading Regions in the Oncolytic Adenovirus Market Expansion Across the Globe?

North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theOncolytic Adenovirus Market Over the Coming Years?

Dominant businesses in the oncolytic adenovirus market are concentrating on collaborative therapies such as VCN-01. This method merges oncolytic virotherapy and chemotherapy to enhance tumor targeting and amplify therapeutic results. VCN-01 is a purposefully engineered oncolytic adenovirus that aims to selectively infect and eliminate cancer cells while also boosting the efficiency of chemotherapy. In May 2024, for instance, Theriva Biologics, a clinical-phase immuno-oncology business located in the United States, reported that the U.S. Food and Drug Administration (FDA) conferred Fast Track Designation (FTD) to their leading candidate, VCN-01. This title is applied to VCN-01 when used alongside gemcitabine and nab-paclitaxel for handling metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that targets and multiplies within tumor cells, assisting in the tumor stroma breakdown, a significant barrier to successful cancer therapy.

View the full report here:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

How Is the Oncolytic Adenovirus Market Conceptually Defined?

Oncolytic adenovirus is a genetically modified virus designed to selectively infect and destroy cancer cells while sparing healthy tissue. It replicates within tumor cells, causing them to rupture and release new viral particles, which further attack the cancer. Additionally, it stimulates the immune system to enhance the body’s anti-tumor response.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21235

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Oncolytic Adenovirus Market Growth Performance Trended Historically, And What Lies Ahead?

The market size for oncolytic adenovirus has witnessed considerable growth lately. It’s projected to rise from $122.31 billion in 2024 to $132.49 billion in 2025, registering a compound annual growth rate (CAGR) of 8.3%. The growth witnessed in the historical period is due to a surge in cancer cases, augmented demand for tailored cancer treatments, an increase in R&D funds, enhancement in delivery procedures, and regulatory approvals.

With a robust increase projected over the coming years, the oncolytic adenovirus market is anticipated to surge to$181.71 billion by 2029 at an 8.2% compound annual growth rate (CAGR). The substantial growth anticipated during this period is attributed to factors such as rising instances and prevalence of cancer, the extension of combination therapies, advancements and approvals in regulations, breakthroughs in virus engineering technology, as well as heightened investment in oncology research. The main trends forecasted during this period involve progresses in viral engineering methodologies, enhanced drug delivery systems, precision improvements in tumor targeting, superior combinations of immunotherapy, and advancements in patient monitoring and diagnostic procedures.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Oncolytic Adenovirus Market?

The relentless rise in cancer cases is set to further stimulate expansion in the oncolytic adenovirus market. This illness, defined by unregulated cell proliferation and dissemination to other body sites, has seen its prevalence escalate due to aging populations, lifestyle choices, environmental exposure, genetic predispositions, and superior detection techniques. Oncolytic adenoviruses specifically target and annihilate cancer cells, presenting a hopeful strategy to counter the mounting number of cancer incidents. For instance, reports released by the National Cancer Institute (NCI), a US governmental body, in May 2024 stated that the world witnessed nearly 20 million fresh cancer cases and 9.7 million fatalities, with a forecast for 2040 to burgeon to approximately 29.9 million cases and 15.3 million deaths. Moreover, statistics from the Australian Bureau of Statistics, a government agency in Australia, showed in 2023 that 1.8% of Australians were diagnosed with cancer, with a slightly higher proportion of men (2.1%) than women (1.6%) being afflicted, particularly those aged 75 and over. Consequently, the escalating occurrence of cancer is propelling the growth trajectory of the oncolytic adenovirus market.

Which Key Market Segments Comprise the Oncolytic Adenovirus Market and Drive Its Revenue Growth?

The oncolytic adenovirusmarket covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses; Adenovirus Type 2-Based Oncolytic Viruses; Other Virus Types

2) By Application: Melanoma; Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Other Applications

3) By End-User: Hospitals; Cancer Research Institutes; Biotechnology Companies; Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based; Second-generation Adenovirus Type 5-based; Engineered Adenovirus Type 5-based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based; Second-generation Adenovirus Type 2-based; Engineered Adenovirus Type 2-based

3) By Other Virus Types: Modified Adenovirus Strains; Hybrid Adenovirus Types; Chimeric Adenoviruses

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp

Which Areas Are Leading Regions in the Oncolytic Adenovirus Market Expansion Across the Globe?

North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theOncolytic Adenovirus Market Over the Coming Years?

Dominant businesses in the oncolytic adenovirus market are concentrating on collaborative therapies such as VCN-01. This method merges oncolytic virotherapy and chemotherapy to enhance tumor targeting and amplify therapeutic results. VCN-01 is a purposefully engineered oncolytic adenovirus that aims to selectively infect and eliminate cancer cells while also boosting the efficiency of chemotherapy. In May 2024, for instance, Theriva Biologics, a clinical-phase immuno-oncology business located in the United States, reported that the U.S. Food and Drug Administration (FDA) conferred Fast Track Designation (FTD) to their leading candidate, VCN-01. This title is applied to VCN-01 when used alongside gemcitabine and nab-paclitaxel for handling metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that targets and multiplies within tumor cells, assisting in the tumor stroma breakdown, a significant barrier to successful cancer therapy.

View the full report here:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

How Is the Oncolytic Adenovirus Market Conceptually Defined?

Oncolytic adenovirus is a genetically modified virus designed to selectively infect and destroy cancer cells while sparing healthy tissue. It replicates within tumor cells, causing them to rupture and release new viral particles, which further attack the cancer. Additionally, it stimulates the immune system to enhance the body’s anti-tumor response.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21235

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Oncolytic Adenovirus Market Growth Performance Trended Historically, And What Lies Ahead?

The market size for oncolytic adenovirus has witnessed considerable growth lately. It’s projected to rise from $122.31 billion in 2024 to $132.49 billion in 2025, registering a compound annual growth rate (CAGR) of 8.3%. The growth witnessed in the historical period is due to a surge in cancer cases, augmented demand for tailored cancer treatments, an increase in R&D funds, enhancement in delivery procedures, and regulatory approvals.

With a robust increase projected over the coming years, the oncolytic adenovirus market is anticipated to surge to$181.71 billion by 2029 at an 8.2% compound annual growth rate (CAGR). The substantial growth anticipated during this period is attributed to factors such as rising instances and prevalence of cancer, the extension of combination therapies, advancements and approvals in regulations, breakthroughs in virus engineering technology, as well as heightened investment in oncology research. The main trends forecasted during this period involve progresses in viral engineering methodologies, enhanced drug delivery systems, precision improvements in tumor targeting, superior combinations of immunotherapy, and advancements in patient monitoring and diagnostic procedures.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Oncolytic Adenovirus Market?

The relentless rise in cancer cases is set to further stimulate expansion in the oncolytic adenovirus market. This illness, defined by unregulated cell proliferation and dissemination to other body sites, has seen its prevalence escalate due to aging populations, lifestyle choices, environmental exposure, genetic predispositions, and superior detection techniques. Oncolytic adenoviruses specifically target and annihilate cancer cells, presenting a hopeful strategy to counter the mounting number of cancer incidents. For instance, reports released by the National Cancer Institute (NCI), a US governmental body, in May 2024 stated that the world witnessed nearly 20 million fresh cancer cases and 9.7 million fatalities, with a forecast for 2040 to burgeon to approximately 29.9 million cases and 15.3 million deaths. Moreover, statistics from the Australian Bureau of Statistics, a government agency in Australia, showed in 2023 that 1.8% of Australians were diagnosed with cancer, with a slightly higher proportion of men (2.1%) than women (1.6%) being afflicted, particularly those aged 75 and over. Consequently, the escalating occurrence of cancer is propelling the growth trajectory of the oncolytic adenovirus market.

Which Key Market Segments Comprise the Oncolytic Adenovirus Market and Drive Its Revenue Growth?

The oncolytic adenovirusmarket covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses; Adenovirus Type 2-Based Oncolytic Viruses; Other Virus Types

2) By Application: Melanoma; Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Other Applications

3) By End-User: Hospitals; Cancer Research Institutes; Biotechnology Companies; Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based; Second-generation Adenovirus Type 5-based; Engineered Adenovirus Type 5-based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based; Second-generation Adenovirus Type 2-based; Engineered Adenovirus Type 2-based

3) By Other Virus Types: Modified Adenovirus Strains; Hybrid Adenovirus Types; Chimeric Adenoviruses

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp

Which Areas Are Leading Regions in the Oncolytic Adenovirus Market Expansion Across the Globe?

North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theOncolytic Adenovirus Market Over the Coming Years?

Dominant businesses in the oncolytic adenovirus market are concentrating on collaborative therapies such as VCN-01. This method merges oncolytic virotherapy and chemotherapy to enhance tumor targeting and amplify therapeutic results. VCN-01 is a purposefully engineered oncolytic adenovirus that aims to selectively infect and eliminate cancer cells while also boosting the efficiency of chemotherapy. In May 2024, for instance, Theriva Biologics, a clinical-phase immuno-oncology business located in the United States, reported that the U.S. Food and Drug Administration (FDA) conferred Fast Track Designation (FTD) to their leading candidate, VCN-01. This title is applied to VCN-01 when used alongside gemcitabine and nab-paclitaxel for handling metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that targets and multiplies within tumor cells, assisting in the tumor stroma breakdown, a significant barrier to successful cancer therapy.

View the full report here:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

How Is the Oncolytic Adenovirus Market Conceptually Defined?

Oncolytic adenovirus is a genetically modified virus designed to selectively infect and destroy cancer cells while sparing healthy tissue. It replicates within tumor cells, causing them to rupture and release new viral particles, which further attack the cancer. Additionally, it stimulates the immune system to enhance the body’s anti-tumor response.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21235

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Oncolytic Adenovirus Market Grown from 2024 to 2025?

The market for oncolytic adenovirus has seen significant growth over the recent years. An increase from $122.31 billion in 2024 to $132.87 billion in 2025, indicative of a compound annual growth rate (CAGR) of 8.6%, is projected. This substantial growth can be traced back to various factors such as a surge in cancer cases, higher demand for specialized cancer treatments, increased funding for research and development activities, enhancements in delivery mechanisms, and regulatory green lights.

What Growth Rate Is Anticipated for the Oncolytic Adenovirus Market in the Coming Years?

Expectations indicate that the oncolytic adenovirus market will experience robust growth in the upcoming years. Its estimated value is projected to reach $183.22 billion by 2029, with a compound annual growth rate (CAGR) of 8.4%. The factors contributing to this projected growth during the forecast period include an increase in cancer cases, advancements and approvals in regulations, enhancement in combination therapies, progress in virus engineering technology, and a rise in oncology research funding. Key trends identified for the forecast period encompass progress in viral engineering methodologies, evolution in drug delivery systems, improvements in tumor targeting accuracy, advancement in combinations of immunotherapy, and developments in diagnostics and patient monitoring.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

Who Are the Leading Companies in the Oncolytic Adenovirus Market?

Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.

What Are the Key Drivers of the Oncolytic Adenovirus Market?

The rise in cancer cases is projected to boost the progression of the oncolytic adenovirus market. Characterized by uncontrolled cellular growth and spread to various body parts, cancer is increasingly prevalent due to a variety of factors such as an aging population, lifestyle choices, exposure to certain environmental factors, genetic vulnerabilities, and enhanced detection methods. The oncolytic adenovirus strategically targets and eliminates cancer cells, presenting a potential solution for the escalating frequency of cancer. For instance, National Cancer Institute (NCI), a US-based governmental agency, reported in May 2024 that there were approximately 20 million fresh cancer cases and 9.7 million fatalities globally, with forecasts for 2040 suggesting 29.9 million cases and 15.3 million deaths. In addition, based on the data from the Australian Bureau of Statistics, a governmental agency in Australia, in 2023, 1.8% of Australians were battling cancer, with a slightly higher occurrence in males (2.1%) than in females (1.6%), most notably among individuals aged 75 and over. Consequently, the escalating numbers of cancer cases are facilitating the growth of the oncolytic adenovirus market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp

What Are the Key Market Segments in the Oncolytic Adenovirus Industry?

The oncolytic adenovirus market covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types

2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications

3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based, Second-generation Adenovirus Type 5-based, Engineered Adenovirus Type 5-based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based, Second-generation Adenovirus Type 2-based, Engineered Adenovirus Type 2-based

3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses

What Are the Latest Trends in the Oncolytic Adenovirus Market?

Prominent firms in the oncolytic adenovirus sector are emphasizing combined therapies such as VCN-01, integrating oncolytic virotherapy and chemotherapy to optimize tumor targeting and bolster therapeutic results. VCN-01 is an oncolytic adenovirus, specifically engineered to infect and obliterate cancer cells while boosting chemotherapy’s potency. For example, Theriva Biologics, an American clinical-stage immunotherapy company, revealed in May 2024 that the U.S. Food and Drug Administration (FDA) awarded Fast Track Designation (FTD) to its prime candidate, VCN-01. This designation applies to VCN-01 when administered in tandem with gemcitabine and nab-paclitaxel to cure metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that zeroes in on and replicates within tumor cells, thus aiding in dismantling the tumor stroma, a notable hindrance to effective cancer treatment.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

What Are the Key Regional Markets in the Oncolytic Adenovirus Industry?

North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21235

This Report Delivers Insight On:

1. How big is the oncolytic adenovirus market, and how is it changing globally?

2. Who are the major companies in the oncolytic adenovirus market, and how are they performing?

3. What are the key opportunities and risks in the oncolytic adenovirus market right now?

4. Which products or customer segments are growing the most in the oncolytic adenovirus market?

5. What factors are helping or slowing down the growth of the oncolytic adenovirus market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

#What is the Anticipated CAGR of the Oncolytic Adenovirus Market, and What Factors Will Drive It?#_x000D_

In recent years, there has been substantial growth in the oncolytic adenovirus market. The market size is projected to escalate from $122.31 billion in 2024 to $132.87 billion in 2025, marking a Compound Annual Growth Rate (CAGR) of 8.6%. Factors contributing to the growth during the historic period include an upsurge in cancer cases, an increased demand for specialized cancer treatments, a surge in R&D funding, enhancement in delivery techniques, and regulatory authorizations._x000D_

_x000D_

There is an anticipated robust expansion in the oncolytic adenovirus market in the upcoming years. This market is predicted to reach $183.22 billion by 2029, recording a compound annual growth rate (CAGR) of 8.4%. The impending growth in the forecasted period can be credited to factors such as the rising prevalence and incidence of cancer, the broadening scope of combination therapies, enhancements in regulatory processes and approvals, evolving innovations in virus engineering, and an increase in funding for oncology research. Key trends throughout this period encompass progress in viral engineering techniques, improved drug delivery systems, precision advancements in tumor targeting, enhanced combinations for immunotherapy, and developments in patient monitoring and diagnostics._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp_x000D_

_x000D_

#What are the Fundamental Drivers and Innovations Shaping the Oncolytic Adenovirus Market?#_x000D_

The escalating cases of cancer are predicted to fuel the expansion of the oncolytic adenovirus market. Characterized by rampant cell growth and its spread to other body parts, cancer’s rising occurrence is influenced by factors such as aging populations, lifestyle habits, environmental factors, genetic susceptibility, and more effective detection methods. Oncolytic adenovirus, which targets and destroys cancer cells selectively, provides a hopeful strategy for addressing the growing prevalence of cancer. For example, in May 2024, the National Cancer Institute (NCI), a US governmental body, released reports indicating nearly 20 million new cancer cases and 9.7 million deaths globally. These figures are expected to climb to 29.9 million cases and 15.3 million deaths by 2040. Furthermore, data from the Australian Bureau of Statistics, an Australia governmental agency, disclosed that 1.8% of Australians were diagnosed with cancer in 2023. The disease affected males (2.1%) more than females (1.6%), particularly in the age group of 75 and above. As a result, the upsurge in cancer cases is propelling growth in the oncolytic adenovirus market._x000D_

_x000D_

#How Is the Oncolytic Adenovirus Market Segmented?#_x000D_

The oncolytic adenovirus market covered in this report is segmented –_x000D_

_x000D_

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types_x000D_

2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications_x000D_

3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes_x000D_

_x000D_

Subsegments:_x000D_

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based, Second-generation Adenovirus Type 5-based, Engineered Adenovirus Type 5-based_x000D_

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based, Second-generation Adenovirus Type 2-based, Engineered Adenovirus Type 2-based_x000D_

3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Oncolytic Adenovirus Market Growth?#_x000D_

North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Key Trends Are Shaping the Future of the Oncolytic Adenovirus Market?#_x000D_

Key players in the oncolytic adenovirus market are directing their efforts towards combination therapies such as VCN-01. This therapy fuses oncolytic virotherapy with chemotherapy with the goal of heightening tumor targeting and augmenting therapeutic results. VCN-01 is a specially engineered oncolytic adenovirus which is designed to selectively infiltrate and decimate cancer cells while simultaneously increasing the potency of chemotherapy. For instance, in May 2024, Theriva Biologics, a clinical-stage immuno-oncology company situated in the U.S., declared that the U.S. Food and Drug Administration (FDA) has conferred Fast Track Designation (FTD) on its premier candidate, VCN-01. This designation is pertinent to VCN-01 when used concomitantly with gemcitabine and nab-paclitaxel in the curative regimen of metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that aims and proliferates within tumor cells, contributing to the disintegration of the tumor stroma, a significant barrier to effective cancer management._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report_x000D_

_x000D_

#How Is the Oncolytic Adenovirus Market Defined and What Are Its Core Parameters?#_x000D_

Oncolytic adenovirus is a genetically modified virus designed to selectively infect and destroy cancer cells while sparing healthy tissue. It replicates within tumor cells, causing them to rupture and release new viral particles, which further attack the cancer. Additionally, it stimulates the immune system to enhance the body’s anti-tumor response._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21235_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Growth Rate of the Oncolytic Adenovirus Market Shape Industry Trends by 2034?

The size of the oncolytic adenovirus market has seen significant expansion recently. The market will escalate from a worth of $122.31 billion in 2024 to $132.87 billion in 2025, with a compound annual growth rate (CAGR) of 8.6%. Numerous factors such as the rise in cancer occurrences, an increasing need for specific cancer treatments, expansion in research and development funding, enhancement in delivery processes, and regulatory green lights are responsible for this growth witnessed in the historic period.

It is predicted that the oncolytic adenovirus market will significantly expand in the coming years, reaching a value of $183.22 billion in 2029 with a compound annual growth rate (CAGR) of 8.4%. This robust growth within the anticipated timeframe can be accredited to factors such as a rising incidence of cancer, the development of combination therapies, progress in regulatory standards and authorizations, technological evolution in virus engineering, and heightened financial support for oncology research. Key market trends during this projected period encompass progressions in viral engineering methodologies, sophisticated drug transportation systems, enhancements in tumor targeting precision, advanced immunotherapy combinations, and developments in patient surveillance and diagnostic techniques.

What External and Internal Drivers Are Contributing to the Growth of the Oncolytic Adenovirus Market’s Growth?

The rising occurrence of cancer is anticipated to spur the growth of the oncolytic adenovirus market in the future. Cancer is identified by unregulated cell growth that can spread to other bodily parts. The escalating rate of cancer is caused by ageing populations, lifestyle influences, exposure to environmental hazards, genetic susceptibilities and enhanced detection methods. Oncolytic adenovirus specifically targets and destroys cancerous cells, presenting a hopeful solution to the growing prevalence of cancer. For instance, the National Cancer Institute (NCI), a US governmental agency, reported in May 2024 that nearly 20 million new cancer cases and 9.7 million deaths were recorded globally, with estimates for 2040 soaring to 29.9 million cases and 15.3 million deaths. In addition, according to the Australian Bureau of Statistics in 2023, 1.8% of Australians were diagnosed with cancer, males (2.1%) were slightly more affected than females (1.6%), especially amongst those aged 75 and over. Therefore, the escalating occurrence of cancer is pushing the growth of the oncolytic adenovirus market.

Get Your Free Sample of the Global Oncolytic Adenovirus Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

Who Are the Key Market Players Influencing the Growth of the Oncolytic Adenovirus Industry?

Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.

What Key Market Trends Are Shaping the Future of the Oncolytic Adenovirus Industry?

Key players in the oncolytic adenovirus marketplace are concentrating on combination treatments such as VCN-01, merging oncolytic virotherapy with chemotherapy to enhance tumor targeting and therapeutic outcomes. VCN-01 is an oncolytic adenovirus geared to selectively infect and destroy cancer cells, also heightening the potency of chemotherapy. For example, in May 2024, Theriva Biologics, a clinical-stage immuno-oncology company based in the US, revealed that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to their leading candidate, VCN-01. This status is conferred to VCN-01 when utilized in combination with gemcitabine and nab-paclitaxel in treating metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that aims and replicates within tumor cells, aiding in deconstructing the tumor stroma, a significant hurdle in effective cancer treatment.

Get Instant Access to the Global Oncolytic Adenovirus Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

What Are the Main Segments of the Oncolytic Adenovirus Market, and How Are They Evolving?

The oncolytic adenovirus market covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types

2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications

3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based, Second-generation Adenovirus Type 5-based, Engineered Adenovirus Type 5-based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based, Second-generation Adenovirus Type 2-based, Engineered Adenovirus Type 2-based

3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses

Which Regions Are Emerging as Leaders in the Oncolytic Adenovirus Market?

North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Defining Features of the Oncolytic Adenovirus Market?

Oncolytic adenovirus is a genetically modified virus designed to selectively infect and destroy cancer cells while sparing healthy tissue. It replicates within tumor cells, causing them to rupture and release new viral particles, which further attack the cancer. Additionally, it stimulates the immune system to enhance the body’s anti-tumor response.

Browse Through More Similar Reports By The Business Research Company:

Deep Vein Thrombosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/deep-vein-thrombosis-global-market-report

Pulmonary Embolism Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

Xenotransplantation Global Market Report 2025

https://thebusinessresearchcompany.com/report/xenotransplantation-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: